$1.03
+0.12 (+13.14%)
Open$0.94
Previous Close$0.91
Day High$1.04
Day Low$0.90
52W High$9.57
52W Low$5.30
Volume—
Avg Volume224.0K
Market Cap58.45M
P/E Ratio27.45
EPS$0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,005.8% upside
Current
$1.03
$1.03
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.47M | 16.16M | 15.23M |
| Net Income | -1,820,896 | -2,032,977 | -1,710,895 |
| Profit Margin | -11.1% | -12.6% | -11.2% |
| EBITDA | -2,687,351 | -2,828,117 | -2,426,513 |
| Free Cash Flow | -1,805,522 | -1,769,464 | -1,134,231 |
| Rev Growth | +21.6% | -2.0% | -5.3% |
| Debt/Equity | 0.65 | 0.64 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |